Ross Chod, MD
Retina Specialist · Aurora, CONPI 1801158548
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,888 of the $10,018 with a category attached, or 78.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations.
Across 187 payments — averaging $53.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$2K
- Genentech USA, Inc.$1K
- AbbVie$1K
- Ocular Therapeutix, Inc.$1K
- Apellis Pharmaceuticals, Inc.$613
- Astellas Pharma US Inc$610
- plus $3K from 16 others
Across 44 payments — averaging $6870.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$204K
- Genentech, Inc.$75K
- Eyepoint US, Inc.$20K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Speaking & faculty fees$1501%
- Travel & lodging$1,75117%
- Food & beverage$7,88879%
- Entertainment$2292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 7 | $1,915 |
| Genentech USA, Inc. | 23 | $1,296 |
| AbbVie(2 entities) | 26 | $1,174 |
| Ocular Therapeutix, Inc. | 13 | $1,164 |
| Apellis Pharmaceuticals, Inc. | 11 | $613 |
| Astellas Pharma US Inc | 20 | $610 |
| Alimera Sciences, Inc. | 13 | $597 |
| Regeneron Healthcare Solutions, Inc. | 12 | $516 |
| Optos, Inc. | 7 | $338 |
| Biogen | 15 | $300 |
| Novartis | 5 | $278 |
| Bausch & Lomb Americas Inc. | 4 | $209 |
| Dutch Ophthalmic, USA | 2 | $206 |
| Notal Vision, Inc. | 4 | $150 |
| Carl Zeiss Meditec USA, Inc. | 2 | $128 |
| ANI Pharmaceuticals, Inc. | 5 | $111 |
| Harrow Eye, LLC | 5 | $105 |
| Coherus Oncology, Inc. | 5 | $100 |
| Mallinckrodt Hospital Products Inc. | 4 | $98 |
| Biotissue Holdings Inc. | 2 | $71 |
| Astellas Pharma Global Development | 1 | $22 |
| Vyera Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,018 in reported general payments places this provider in the 65th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 115 | $5,996 |
| Ofloxacin | 87 | $1,285 |
| Ketorolac Tromethamine | 17 | $572 |
| Brimonidine Tartrate | 13 | $540 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $297 |
| ErythromycinErythromycin Base | 13 | $141 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Aurora
- Talisa ForestAurora$84K
- Lynn HassmanAurora$16K
- Zachary KoretzAurora$14K
- Niranjan ManoharanAurora$9K
- Amit ReddyAurora$4K
- Rachel ChenAurora$4K
- Naresh MandavaAurora$3K
- Frank SiringoAurora$3K
- Abraham HangAurora$2K
- Sean RodriguezAurora$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.